Thompson Tommy G

Director Tommy G Thompson sold 2,000 shares at blended average $539.17; holdings now 8,480 shares post-transaction.

Thompson sold 3 separate tranches on 2026-03-26 for a combined $1,078,332.28, leaving him with 8,480 shares post-transaction. His prior 4 sales at UTHR all underperformed in hindsight: each showed positive 30-day and 90-day returns, with the most recent sale (2025-09-10) yielding +9.1% in 30 days and +18.1% in 90 days, indicating these sales preceded stock appreciation rather than declines. Current price of $532.53 sits only 1.2% below his blended sale price, and UTHR's fundamentals remain solid (P/E 16.54, annual revenue growth +10.6%, net income $338.7M in the latest quarter). The timing of this sale relative to recent 12.5% monthly and 5.0% quarterly gains offers context, but the pattern of his prior UTHR sales all being followed by gains suggests this director has not historically sold into weakness.

Director Thompson buys 8,400 shares of TXMD at $1.67; holdings surge 56.8%; prior TXMD buy achieved 17.8% 90d gain.

Director Tommy G Thompson purchased 8,400 shares of TherapeuticsMD at $1.67, increasing his holdings by 56.8% to 23,179 shares. His prior purchase of TXMD stock on 2025-04-14 delivered a 17.8% 90-day return, establishing a pattern of well-timed accumulation at this ticker. The stock currently trades at $1.68, near the transaction price, within its 52-week range and 56.3% above its 90-day low. The company posted $784,000 quarterly revenue and $152,000 net income, though the full fiscal year was unprofitable. The acquisition follows recent positive price momentum while the company remains early-stage, with a P/E of 56.00 and a $19.4M market cap.

Director Thompson sold 4,560 shares ($1.8M) at $403.36; stock now -3.3% from 52-week high after +32.0% 30-day surge

Tommy G Thompson, a director, sold 4,560 shares (35.0% of his pre-transaction holdings) for $1,839,321.60 at $403.36 on 2025-09-10. The current price of $396.50 sits 3.3% below the 52-week high of $410.00, while the stock has posted strong recent momentum with a +32.0% gain over the past 30 days and a +38.6% gain over 90 days. Thompson's prior three sales at UTHR generated 90-day returns of +6.1%, +5.6%, and +5.4%—all positive outcomes, indicating his past sells at this ticker did not precede price declines. The fundamentals remain robust: revenue of $798,600,000.00 in the latest quarter, net income of $309,500,000.00, annual revenue growth of +23.6%, and a P/E of 14.44. The sale occurs after sustained price appreciation and against a backdrop of strong operational performance, leaving timing relative to near-term direction unclear.

Director Tommy G Thompson buys 5,777 shares of Healthpeak Properties at $17.27; stock down 13.7% in 90 days

Director Thompson purchased 5,777 shares at $17.27 on 2025-05-28, increasing his holdings from 138,513 to 144,290 shares—a modest 4.2% addition to existing position. The purchase occurred while the stock trades at $17.41 (current price), down 13.7% over the past 90 days and 24.7% below its 52-week high of $23.12. Thompson's prior open-market trade at this ticker occurred just 19 days earlier (2025-05-09 buy), and outcomes remain unmeasurable; his cross-ticker track record shows 2 prior buys with an average 30-day return of +3.8%, but no pattern of well-timed purchases at the 90-day mark across his broader history. The company reports strong fundamentals—$702.9M quarterly revenue (+23.8% annual growth) and a P/E of 43.52—but the stock's recent weakness and this director's recent repurchase activity following an earlier buy warrant observation rather than confident interpretation.

Director Thompson Tommy G buys 5,700 shares of HEALTHPEAK PROPERTIES at $17.36; 6 other insiders also bought in past 14 days (cluster pattern).

Director Tommy G Thompson purchased 5,700 shares at $17.36 on 2025-05-09, increasing his holdings from 132.8K shares to 138.5K shares. This purchase is noteworthy for its placement within a cluster: 6 other insiders also bought within the past 14 days, suggesting coordinated or independent but synchronized appetite at the current price level. The stock currently trades at $17.55, having declined 3.4% over the past 30 days and 10.5% over 90 days, positioning this buy approximately 24.1% below the 52-week high of $23.12. While Thompson's cross-ticker track record shows only 1 prior buy against 3 prior sells (averaging 11.8% 90-day returns), the multi-insider cluster buy pattern may signal perceived value at recent price levels, though the company's elevated P/E of 43.88 against $12.2B market cap warrants investor attention to valuation context.

Director Tommy G Thompson buys 325 TXMD shares at $1.00; holder of 14.8K shares, stock down 53.2% from 52-week high.

Director Thompson G purchased 325 shares of TherapeuticsMD at $1.00, increasing his holdings to 14,779 shares. The company is unprofitable, posting quarterly revenue of $-53.0K and net income of $-1.1M in the latest period, though full-year revenue growth of 35.2% shows operating expansion. The stock trades at $1.04 currently, having fallen 53.2% from its 52-week high of $2.22 while rebounding 43.4% over the past 30 days. This modest share purchase—worth $325.59—represents a small addition to existing holdings (2.2% increase) and lacks the scale or context to indicate a conviction-driven accumulation stance.

Director Thompson Tommy G sold 7,500 shares (46.9% reduction) at $319.34 blended average; stock near 52-week high of $319.04.

Thompson Tommy G executed 3 separate sales totaling 7,500 shares for $2,395,035.39 on 2024-06-26, reducing his holdings from 16.0K to 8.5K shares—a 46.9% reduction of his pre-transaction position. The sales occurred at prices ($318.81, $320.21, $320.84) at or near the 52-week high of $319.04, with the current price at $318.55 only 0.2% below the 52-week high. The timing coincides with strong stock momentum (90-day change +38.7%, 30-day change +19.0%), while the company shows solid fundamentals (P/E 13.45, net income of $306.6M, annual revenue growth of +20.2%). The large reduction in his director-level stake warrants observation given the proximity to all-time highs and the magnitude of the liquidation.